(Q34401791)

1 August 2017

1 reference

title

Glucagon-like peptide 1(GLP-1) in biology and pathology (English)

1 reference

1 August 2017

Juris J Meier

1

1 reference

1 August 2017

Michael A Nauck

series ordinal

2

1 reference

1 August 2017

language of work or name

1 reference

1 March 2005

1 reference

Diabetes - Metabolism: Research and Reviews

1 August 2017

published in

1 reference

1 August 2017

volume

21

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

91-117

1 reference

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

1 August 2017

cites work

1 reference

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin

21 January 2018

1 reference

Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans

21 January 2018

1 reference

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

21 January 2018

1 reference

Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats

21 January 2018

1 reference

Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect

21 January 2018

1 reference

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs

21 January 2018

1 reference

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.

21 January 2018

1 reference

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

21 January 2018

1 reference

7 January 2021

Intestinal Factors in the Control of Insulin Secretion

1 reference

7 January 2021

The incretin concept today

1 reference

7 January 2021

Gut hormones and diabetes mellitus

1 reference

7 January 2021

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

7 January 2021

Incretin effect due to increased secretion and decreased clearance of insulin in normal humans

1 reference

7 January 2021

Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans

1 reference

7 January 2021

Further purification of a polypeptide demonstrating enterogastrone activity

1 reference

7 January 2021

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

1 reference

7 January 2021

A Gastric Inhibitory Polypeptide. I. The Amino Acid Composition and the Tryptic Peptides

1 reference

7 January 2021

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

7 January 2021

The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas

1 reference

7 January 2021

Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas

1 reference

7 January 2021

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

1 reference

7 January 2021

The glucagon superfamily: precursor structure and gene organization

1 reference

7 January 2021

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

7 January 2021

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

7 January 2021

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

1 reference

7 January 2021

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

1 reference

7 January 2021

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

1 reference

7 January 2021

Glucagon-like peptide-1 and the entero-insular axis in obese hyperglycaemic (ob/ob) mice

1 reference

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

7 January 2021

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

1 reference

7 January 2021

Immunohistochemical localization of glucagon-like peptide 1. Use of poly- and monoclonal antibodies

1 reference

7 January 2021

Identification of the intestinal cell storing gastric inhibitory peptide

1 reference

7 January 2021

Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man

1 reference

7 January 2021

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

1 reference

7 January 2021

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

1 reference

7 January 2021

Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects.

1 reference

7 January 2021

Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men.

1 reference

7 January 2021

Interaction between specific fatty acids, GLP-1 and insulin secretion in humans

1 reference

7 January 2021

Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus

1 reference

7 January 2021

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

1 reference

7 January 2021

Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection

1 reference

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

7 January 2021

Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides

1 reference

7 January 2021

Gastric emptying and release of incretin hormones after glucose ingestion in humans

1 reference

7 January 2021

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop

1 reference

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

7 January 2021

Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats

1 reference

7 January 2021

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

1 reference

7 January 2021

Attenuated GLP-1 secretion in obesity: cause or consequence?

1 reference

7 January 2021

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

7 January 2021

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

7 January 2021

High potency antagonists of the pancreatic glucagon-like peptide-1 receptor

1 reference

7 January 2021

The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide

1 reference

7 January 2021

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

1 reference

7 January 2021

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1 reference

7 January 2021

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

1 reference

7 January 2021

Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase)

1 reference

7 January 2021

Renal catabolism of human glucagon-like peptides 1 and 2

1 reference

7 January 2021

Lipolytic action of glucagon-like peptides in isolated rat adipocytes

1 reference

7 January 2021

Chronic renal failure: effect of hemodialysis on gastrointestinal hormones.

1 reference

7 January 2021

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

1 reference

7 January 2021

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

1 reference

7 January 2021

Effect of glucagon-like peptide-1 on insulin secretion

1 reference

7 January 2021

Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone

1 reference

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

7 January 2021

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

1 reference

7 January 2021

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

1 reference

7 January 2021

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

7 January 2021

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

7 January 2021

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

1 reference

7 January 2021

Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release

1 reference

7 January 2021

Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization

1 reference

7 January 2021

Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors

1 reference

7 January 2021

Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic -Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling

1 reference

7 January 2021

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

1 reference

7 January 2021

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

7 January 2021

Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo.

1 reference

7 January 2021

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

1 reference

7 January 2021

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

7 January 2021

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

1 reference

7 January 2021

Distribution of GLP-1 and PACAP receptors in human tissues

1 reference

7 January 2021

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

7 January 2021

Physiology of glucose homeostasis

1 reference

7 January 2021

Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects

1 reference

7 January 2021

Gastric emptying in diabetes: clinical significance and treatment.

1 reference

7 January 2021

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

7 January 2021

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

7 January 2021

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

7 January 2021

Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans

1 reference

7 January 2021

Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans

1 reference

7 January 2021

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

1 reference

7 January 2021

Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat

1 reference

7 January 2021

GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans

1 reference

7 January 2021

Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man

1 reference

7 January 2021

Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.

1 reference

7 January 2021

Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man

1 reference

7 January 2021

Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs

1 reference

7 January 2021

Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus

1 reference

7 January 2021

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

1 reference

7 January 2021

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

1 reference

7 January 2021

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

1 reference

7 January 2021

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

7 January 2021

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

1 reference

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

7 January 2021

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

1 reference

7 January 2021

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

7 January 2021

Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis.

1 reference

7 January 2021

beta-cell apoptosis: stimuli and signaling

1 reference

7 January 2021

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

1 reference

7 January 2021

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

1 reference

7 January 2021

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

1 reference

7 January 2021

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

7 January 2021

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

1 reference

7 January 2021

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

1 reference

7 January 2021

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

1 reference

7 January 2021

Stimulated endocrine cell proliferation and differentiation in transplanted human pancreatic islets: effects of the ob gene and compensatory growth of the implantation organ.

1 reference

7 January 2021

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

1 reference

7 January 2021

Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells

1 reference

7 January 2021

Glucose-stimulated preproinsulin gene expression and nuclear trans-location of pancreatic duodenum homeobox-1 require activation of phosphatidylinositol 3-kinase but not p38 MAPK/SAPK2.

1 reference

7 January 2021

Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells

1 reference

7 January 2021

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

1 reference

7 January 2021

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

1 reference

7 January 2021

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

1 reference

7 January 2021

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes

1 reference

7 January 2021

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes

1 reference

7 January 2021

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

1 reference

7 January 2021

Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor

1 reference

7 January 2021

1 reference

7 January 2021

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

1 reference

7 January 2021

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

1 reference

7 January 2021

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

1 reference

7 January 2021

Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats

1 reference

7 January 2021

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

1 reference

7 January 2021

Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats

1 reference

7 January 2021

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

1 reference

7 January 2021

Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells

1 reference

7 January 2021

Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line

1 reference

7 January 2021

New developments in the incretin concept

1 reference

7 January 2021

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

1 reference

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

7 January 2021

Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog

1 reference

7 January 2021

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

7 January 2021

Immunoreactive gastric inhibitory polypeptide

1 reference

7 January 2021

Enhancement of cellulose production by expression of sucrose synthase in Acetobacter xylinum

1 reference

7 January 2021

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

1 reference

7 January 2021

Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats

1 reference

7 January 2021

Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption

1 reference

7 January 2021

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

1 reference

7 January 2021

Glucagon-like peptide-1 is a physiological incretin in rat

1 reference

7 January 2021

Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

1 reference

7 January 2021

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

1 reference

7 January 2021

Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti

1 reference

7 January 2021

Is glucagon-like peptide 1 an incretin hormone?

1 reference

7 January 2021

Secretin inhibits gastric acid secretion via a vagal afferent pathway in rats.

1 reference

7 January 2021

Enterogastrone-like effect of peptide YY is vagally mediated in the dog

1 reference

7 January 2021

Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate

1 reference

7 January 2021

Effect of truncated glucagon-like peptide 1 on cAMP in rat gastric glands and HGT-1 human gastric cancer cells

1 reference

7 January 2021

Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands

1 reference

7 January 2021

Ileal release of glucagon-like peptide-1 (GLP-1)

1 reference

7 January 2021

Glucagon-like peptide-1: a potent regulator of food intake in humans

1 reference

7 January 2021

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

1 reference

7 January 2021

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

1 reference

7 January 2021

Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy

1 reference

7 January 2021

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

1 reference

7 January 2021

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

1 reference

7 January 2021

1 reference

7 January 2021

Renal catabolism of truncated glucagon-like peptide 1

1 reference

7 January 2021

Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.

1 reference

7 January 2021

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

7 January 2021

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1

1 reference

7 January 2021

Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

1 reference

7 January 2021

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

1 reference

7 January 2021

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

7 January 2021

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

7 January 2021

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

7 January 2021

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

7 January 2021

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

1 reference

7 January 2021

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

1 reference

7 January 2021

Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide

1 reference

7 January 2021

Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects

1 reference

7 January 2021

Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

1 reference

7 January 2021

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

1 reference

7 January 2021

Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats

1 reference

7 January 2021

The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation

1 reference

7 January 2021

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

1 reference

7 January 2021

1 reference

7 January 2021

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

1 reference

7 January 2021

Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia

1 reference

7 January 2021

Inhibition of gastrin release by gastric inhibitory peptide mediated by somatostatin

1 reference

7 January 2021

Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects

1 reference

7 January 2021

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

1 reference

7 January 2021

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

1 reference

7 January 2021

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

1 reference

7 January 2021

Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics*

1 reference

7 January 2021

Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus.

1 reference

7 January 2021

Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM

1 reference

7 January 2021

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

1 reference

7 January 2021

Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.

1 reference

7 January 2021

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

1 reference

7 January 2021

GLP-1 as a satiety factor in children with eating disorders

1 reference

7 January 2021

Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action

1 reference

7 January 2021

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

1 reference

7 January 2021

HYPERINSULINISM-HYPOGLYCEMIA IN THE POSTGASTRECTOMY PATIENT

1 reference

7 January 2021

Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy

1 reference

7 January 2021

Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome

1 reference

7 January 2021

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

1 reference

7 January 2021

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis

1 reference

7 January 2021

A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes.

1 reference

7 January 2021

Intestinal proliferation and delayed intestinal transit in a patient with a GLP-1-, GLP-2- and PYY-producing neuroendocrine carcinoma

1 reference

7 January 2021

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

1 reference

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

7 January 2021

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

1 reference

7 January 2021

Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM

1 reference

7 January 2021

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

1 reference

7 January 2021

Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

1 reference

7 January 2021

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

1 reference

7 January 2021

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

1 reference

7 January 2021

Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus

1 reference

7 January 2021

Disordered gastric motor function in diabetes mellitus

1 reference

7 January 2021

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus

1 reference

7 January 2021

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

1 reference

7 January 2021

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

1 reference

7 January 2021

Prevalence of impaired glucose tolerance among children and adolescents with marked obesity

1 reference

7 January 2021

Inhibition of food intake in obese subjects by peptide YY3-36

1 reference

7 January 2021

Simulated postaggression metabolism in healthy subjects: metabolic changes and insulin resistance

1 reference

7 January 2021

Alterations in carbohydrate metabolism during stress: a review of the literature

1 reference

7 January 2021

Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.

1 reference

7 January 2021

Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview

1 reference

7 January 2021

Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview

1 reference

7 January 2021

Intensive insulin therapy in critically ill patients

1 reference

7 January 2021

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

1 reference

7 January 2021

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

7 January 2021

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

7 January 2021

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

7 January 2021

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

7 January 2021

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

1 reference

7 January 2021

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

1 reference

7 January 2021

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

1 reference

7 January 2021

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

7 January 2021

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

7 January 2021

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

1 reference

7 January 2021

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

7 January 2021

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

7 January 2021

Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.

1 reference

7 January 2021

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

1 reference

7 January 2021

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

1 reference

7 January 2021

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

7 January 2021

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

7 January 2021

1 reference

7 January 2021

Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances

1 reference

7 January 2021

Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs

1 reference

7 January 2021

Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes

1 reference

7 January 2021

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients

1 reference

7 January 2021

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

1 reference

7 January 2021

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.538

1 reference

1 August 2017

1 reference